A glomerular disease characterized by a marked loss of protein in the urine is

Sections

Proteinuria

• Sections Proteinuria

• Overview
• Presentation
• DDx
• Workup
• Treatment
• Medication
• Questions & Answers
• References

Overview

Practice Essentials

The detection of proteins excreted in the urine has been extensively used in the assessment of kidney diseases. Proteinuria identifies patients with kidney damage and those at risk for worsening kidney disease and increased cardiovascular morbidity. An individual with proteinuria in the setting of a normal glomerular filtration rate (GFR) is at high risk of progressive loss of kidney function. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the evaluation and management of chronic kidney disease (CKD) includes proteinuria in the staging of CKD. It is important to note when proteinuria is present and can be reduced, as lowering proteinuria has a protective effect against further loss of kidney function.

Normal urinary protein excretion is < 150 mg/24 hours and consists mostly of secreted proteins such as Tamm-Horsfall proteins. The normal mean albumin excretion rate (AER) is 5-10 mg/day, with an AER of > 30 mg/day considered abnormal. AER between 30 to 300 mg/day is called moderately increased albuminuria. Levels greater than 300 mg/day are called severely increased albuminuria. In the past, moderately and severely increased albuminuria were referred to as microalbuminuria and macroalbuminuria, respectively. Albuminuria that persists for 3 months is considered CKD. Nephrotic-range proteinuria is defined as greater than 3.5 g of protein excreted in the urine over 24 hours. [1, 2]

Proteinuria can be differentiated on the basis of any of the following:

• Amount of protein (nephrotic or non-nephrotic)

• Type of protein (albuminuria or low molecular weight proteinuria)

• Underlying pathological damage (glomerular vs non-glomerular).

Pathophysiologically, most cases of proteinuria are classified into one or more of  the following categories:

• Tubular

• Overflow

• Glomerular

Tubular proteinuria

Tubular proteinuria is a result of tubulointersitial disease affecting the proximal renal tubules and interstitium. This results in decreased proximal reabsorption of proteins—in particular, low molecular weight proteins (generally below 25,000 Daltons) such as beta-2 microglobulin. Under normal conditions these proteins are completely reabsorbed in the proximal tubules. The amount of proteinuria is usually < 2 g/day and dipstick results may be negative.

Causes of tubular proteinuria include the following:

• Acute interstitial nephritis

• Immunosuppressive agents

• Analgesics

• Cryoglobulinemia

• Sjögren syndrome

Overflow proteinuria

Overflow proteinuria is most commonly associated with increased production of abnormal low molecular weight proteins (eg, light chains in multiple myeloma, myoglobin in rhabdomyolysis) that exceeds the reabsorption capacity of the proximal tubule, leading to spilling of the protein into the urine. These low molecular proteins can be toxic to the tubules and can cause acute kidney injury. For example, paraprotein deposition can induce a glomerulopathy leading to the additional loss of albumin and more profound proteinuria.

Glomerular proteinuria

Glomerular proteinuria associated with pathological damage to the glomerulus is categorized by protein quantity; the more severe the proteinuria, the more significant the glomerular disease. The primary protein lost is albumin. These patients require close follow-up and may need a kidney biopsy if they have abnormal urine microscopy results and/or impairment of kidney function. 

Glomerular proteinuria can also be categorized according to whether pathological damage of the glomerulus is present. Types that do not result from pathological damage to the glomerulus include transient and orthostatic proteinuria.

Transient proteinuria occurs in persons with normal kidney function, bland urine sediment, and normal blood pressure. The quantitative protein excretion is less than 1 g/day. The proteinuria is not indicative of significant underlying kidney disease; it may be precipitated by high fever or heavy exercise, and it disappears upon repeat testing. Exercise-induced proteinuria usually resolves within 24 hours. 

Orthostatic proteinuria is diagnosed if the patient has no proteinuria in early morning samples but has low-grade proteinuria at the end of the day. It usually occurs in tall, thin adolescents or adults younger than 30 years (and may be associated with severe lordosis). Patients have normal kidney function and proteinuria is usually < 1 g/day, with no hematuria. The diagnosis of orthostatic proteinuria is made by collecting the urine from the first morning void after the patient has been recumbent overnight. It is associated with good long-term prognosis. [3, 4, 5]

Accompanying findings in patients with glomerular damage may include the following (see ):

• Active urine sediment - Dysmorphic red blood cells and red cell casts

• Hypoalbuminemia

• Lipiduria

• Hyperlipidemia

• Edema

• Abnormal kidney function

• Hypertension

Isolated, post-renal, and post-transplant proteinuria also deserve mention. Isolated proteinuria is proteinuria without any abnormalities in urinary sediment, hematuria, or a reduction in GFR and in the absence of hypertenson and diabetes. Isolated proteinuria is usually found on routine urinalysis in the non-nephrotic range. It is caused by damage to tubular cells or the lower urinary tract. Post-renal proteinuria occurs with inflammation of the urinary tract. Common conditions thought to be associated with post-renal proteinuria are urinary tract infection, nephrolithiasis, and tumors of the urinary tract. Post-renal proteinuria usually resolves when the underlying condition has resolved.

Post-transplant proteinuria occurs in about 45% of kidney transplant recipients. Typically, proteinuria from native kidneys dramatically falls after transplant. Proteinuria at levels comparable with before transplantation is a sign of damage. The common causes of post-transplant proteinuria include the following:

• Drug toxicity

• Transplant glomerulopathy

• Interstitial fibrosis and tubular atrophy,

• Rejection

Physiology

Plasma proteins are essential components of any living being. The kidneys play a major role in the retention of plasma proteins; the renal tubules reabsorb these proteins as they pass through the glomerular filtration barrier. Normal urine protein excretion is up to 150 mg/day. Therefore, the detection of abnormal quantities or types of protein in the urine is considered an early sign of significant kidney or systemic disease. (See and .)

Complications

Complications of proteinuria include the following (see ):

• Pulmonary edema due to fluid overload

• Acute kidney failure due to intravascular depletion

• Increased risk of bacterial infection, including spontaneous bacterial peritonitis

• Increased risk of arterial and venous thrombosis, including renal vein thrombosis

• Increased risk of cardiovascular disease

See Pediatric Proteinuria for discussion of the condition in that population.

Next:

Pathophysiology

Currently, the development of proteinuria is thought to involve dysfunction of the glomerular filtration barrier, tubular dysfunction, or both. 

The glomerular filration barrier seperates the kidney vasculature from the urinary space. One of the barrier's primary purposes is to prevent the passage of plasma proteins notably albumin. The small amount of albumin and non-albumin protein that is filtered is reabsorbed in the proximal convoluted tubule (PCT).

The three components of the glomerular filtration barrier are the podocytes (epithelial cells), the fenestrated endothelial cells, and the glomerular basement membrane (GBM). Proteinuria is prevented by the negative charge and size selectivity of the glomerular filtration barrier. Crosstalk among podocytes, mesangium, and endothelium maintains the normal filtration barrier. As all three are interlinked, damage to any one of them affects the functioning of the others. 

Podocytes are the terminally differentiated visceral epithelial cells of the glomerulus found outside of the glomerular capillares; they face the Bowman space and the tubular infiltrate. Podocytes cover the glomerular capillaries and have extensions called foot processes that interdigitate with neighboring podoctyes, forming slit diaphragms 25-60 nm in size. Changes or effacement of foot processes is seen in many proteinuric states. Mutations in the genes that code for the proteins comprising the structure of the slit diaphragm can result in overt proteinuria.    

Glomerular capillaries are internally lined by endothelial cells that are in contact with the bloodstream. A unique feature of glomerular endothelial cells is their fenestrations—holes in the cell that permit passage of fluid across the glomerular capillary wall. Although these fenestrations are much larger than albumin, the endothelial surface has a covering coat made up of negatively charged glycocalyx, glycosaminoglycans and proteoglycans that retards the positively charged albumin and other plasma proteins. This cellular coat acts as both a size- and charge-based barrier. In addition, endothelium activation and loss of selectivity leads to prolonged exposure of podocytes to proteins. This results in the activation of renin-angiotensin in podocytes [6] and alteration of size selectivity. Damage to podocytes in turns leads to decrease in vascular endothelial growth factor (VEGF) required for endothelial fenestrae formation.  [7]

The glomerular fitration barrier is also maintained by the mesangium's mesangial cells.  Mesangial cells lie close to the capillary lumen and play an important role in glomerular hemodynamics and immune complex clearance. The mesangial cells produce a matrix made up of collagen, fibronectin, and proteglycans that supports the glomerular capillaries. This is a common site of deposition of circulating immune complexes. The mesangium is disrupted by cell proliferation, as occurs in diabetic nephropathy or immunoglonin A (IgA) nephropathy. [8]

The GBM is made up of type IV collage, laminin, nidogen/entactin, sulfated proteoglycans, and glycoproteins. The GBM limits fluid movement. Changes in the proteins that make up the GBM, leading to proteinuria, have been described in congenital and acquired nephrotic syndrome. Proteinuria itself can cause endothelial damage: protein-mediated cytotoxicity may result in podocyte loss, leading to the production of chemokines and cytokines that initiate an inflammatory response. The end point is sclerosis and fibrosis of the glomerulus.  [9]

High amounts of albumin are filtered in the proximal tubules, and the mechanism is thought to involve two receptors, which can process 250 g of albumin per day. Obviously, any dsyfunction in this protein retrieval pathway wouldl result in nephrotic syndrome.    

Previous

Next:

Etiology

The presence of abnormal amounts or types of protein in the urine may reflect any of the following:

• Systemic diseases that result in an inability of the kidneys to normally reabsorb the proteins through the renal tubules

• Overproduction of plasma proteins that are capable of passing through the normal glomerular basement membrane (GBM) and that consequently enter the tubular fluid in amounts that exceed the capacity of the normal proximal tubule to reabsorb them

• A defective glomerular barrier that allows abnormal amounts of proteins of intermediate molecular weight to enter the Bowman space

Glomerular disease

Causes of glomerular disease can be classified as primary (no evidence of extrarenal disease) or secondary (kidney involvement in a systemic disease) and can then subdivided within these two groups on the basis of the presence or absence of nephritic/active urine sediment. In some cases, however, primary and secondary diseases can produce identical renal pathology.

Primary glomerular diseases associated with active urine sediment (proliferative glomerulonephritis) include the following

• Immunoglobulin A (IgA) nephropathy

• Membranoproliferative glomerulonephritis (MPGN)

• Mesangial proliferative glomerulonephritis

Primary glomerular diseases associated with bland urine sediment (nonproliferative glomerulonephritis) include the following:

• Membranous glomerulonephritis [10]

• Minimal-change disease

• Primary focal segmental glomerulosclerosis

• Fibrillary glomerulonephritis

• Immunotactoid glomerulonephritis

Secondary glomerular diseases associated with active urine sediment (proliferative glomerulonephritis, including rapidly progressive glomerulonephritis) include the following:

• Anti-GBM disease

• Renal vasculitis - Including disease associated with antineutrophil cytoplasmic antibodies (ANCAs), such as granulomatosis with polyangiitis (formerly known as Wegener granulomatosis)

• Lupus nephritis [11]

• Cryoglobulinemia-associated glomerulonephritis

• Bacterial endocarditis

• Henoch-Schönlein purpura

• Postinfectious glomerulonephritis

Secondary glomerular diseases associated with bland urine sediment (nonproliferative glomerulonephritis) include the following:

• Diabetic nephropathy

• Amyloidosis

• Hypertensive nephrosclerosis

• Light-chain disease from multiple myeloma

• Secondary focal glomerulosclerosis

Secondary focal glomerulosclerosis may result from the following:

• The healing phase of other glomerulonephritides

• As a nonspecific result of reduced nephron mass from any cause, including nonglomerular diseases such as reflux nephropathy

• Other causes of glomerular hyperfiltration, such as hypertensive nephrosclerosis and obesity

Unlike primary focal segmental glomerulosclerosis, the secondary type usually is gradual in onset and is not usually associated with hypoalbuminemia or other manifestations of nephrotic syndrome, even in the presence of nephrotic-range proteinuria.

MPGN is usually a pattern of injury seen on light microscopy. The current immunofluorescence-based classification divides MPGN as follows [12] :

• Immunoglobulin- and complement-positive MPGN

• Complement-positive MPGN - Due to dysregulation of complement pathway; includes C3 glomerulonephritis and dense-deposit disease

• Thrombotic microangiopathy (immunoglobulin and complement negative)

Other causes of proteinuria include the following:

• Neoplasms: Carcinoma (eg, bronchus, breast, colon, stomach, kidney), leukemia, lymphomas, melanomas

• Medications/drugs: Heroin, interferon alfa, lithium, nonsteroidal anti-inflammatory drugs, pamidronate, sirolimus

• Viral Infections: Epstein-Barr virus, hepatitis B and C viruses, herpes zoster, human immunodeficiency virus

• Allergic: Antitoxins, insect stings, poison ivy

• Genetic: Hereditary nephritis ( Alport syndrome)

• Other causes: Castleman disease, malignant hypertension, pre-eclampsia, transplant glomerulopathy 

In patients with cancer, treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) has been associated with an increased risk of developing proteinuria. A meta-analysis of randomized controlled trials of five newly approved VEGFR-TKIs (regorafenib, vandetanib, cabozantinib, lenvatinib, axitinib)  found an increased risk of episodes of all-grade proteinuria (relative risk [RR] 2.35, 95% confidence index [CI] 1.69-3.27, P < 0.001) and high-grade proteinuria (RR 3.70, 95% CI 2.09-6.54, P < 0.001). [13]

On subgroup analysis, risk of all-grade proteinuria was significantly increased with lenvatinib, axitinib, and vandetanib, while risk of high-grade proteinuria was increased with lenvatinib. In addition, the risk of experiencing high-grade proteinuria was significant for patients with hepatocellular carcinoma and renal cell carcinoma, but not for patients with colorectal cancer and thyroid cancer. [13]

Previous

Next:

Epidemiology

Occurrence in the United States

In the third National Health and Nutrition examination Survey (NHANES III), the prevalence of albuminuria in the US population was found to be 6.1% in males and 9.7 % in females. The prevalence of albuminuria was 28.8% in persons with diabetes, 16.0% in those with hypertension, and 5.1% in those without diabetes, hypertension, cardiovascular disease, or elevated serum creatinine levels. The prevalence of proteinuria starts increasing at 40 years of age. Also, 3.3% of the US adult population was found to have persistent albuminuria with a normal estimated glomerular filtration rate (eGFR). [14]

Race-related demographics

According to the NHANES III survey, the prevalence of microalbuminuria is greater in non-Hispanic blacks and Mexican Americans aged 40 to 79 years compared with age-matched non-Hispanic whites. Similar results were found in the NHANES survey from 2006, where even after adjusting for covariates and medication use, racial and ethnic minorities with and without diabetes had greater odds of albuminuria compared with whites without diabetes. The results were similar when the comparison was made in patients with eGFR < 60 mL/min. [15, 16]

Many causes of proteinuria are particularly common in African Americans and certain other groups. The primary glomerular disorder, focal segmental glomerulosclerosis, has a higher incidence as well as a worse prognosis in African Americans.

In a study by Friedman et al, nondiabetic chronic kidney disease was found to occur in more than 3 million African Americans who had genetic variants in both copies of APOL1, increasing their risk for hypertension-attributable end-stage renal disease and focal segmental glomerulosclerosis. However, African Americans without the risk genotype appear to have a risk similar to that of European Americans for developing nondiabetic chronic kidney disease. [17]

Sex- and age-related demographics

Most primary glomerular diseases associated with proteinuria (eg, membranous glomerulonephritis) and secondary renal diseases (eg, diabetic nephropathy) are more common in males than in females. As a result, persistent proteinuria is at least twice as common in males as in females.

The incidence of hypertension and diabetes increases with age. In consequence, the incidence of persistent proteinuria (and microalbuminuria) also increases with age.

Previous

Next:

Prognosis

The prognosis for patients with proteinuria depends on the cause, duration, and degree of the proteinuria. Young adults with transient or orthostatic proteinuria have a benign prognosis, while patients with hypertension and microalbuminuria (or higher degrees of albuminuria) have a significantly increased risk of cardiovascular disease.

Proteinuria has been associated with progression of kidney disease, [18] increased atherosclerosis, and left ventricular abnormalities indirectly contributing to cardiovascular morbidity and mortality. In addition to being a predictor of outcome in patients with renal disease, microalbuminuria also is a predictor of morbidity and mortality in patients who do not have evidence of significant renal disease.

In the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study, which included 769 patients who experienced AKI during hospitalization, a higher urine albumin-to-creatinine ratio (ACR) quantified 3 months after hospital discharge was associated with increased risk of kidney disease progression. The hazard ratio was 1.53 for each doubling of ACR (95% confidence index, 1.45-1.62), and urine ACR measurement was a strong discriminator for future kidney disease progression. [19]

In patients with hypertension, the presence of microalbuminuria correlates with the presence of left ventricular hypertrophy. In both hypertensive and normotensive patients, the presence of microalbuminuria predicts an increased risk of cardiovascular morbidity and mortality.

Cardiovascular outcomes and proteinuria

In a study of 2310 patients, Jackson et al concluded that spot urinary albumin-to-creatinine ratios (UACRs) have significant prognostic value in persons with heart failure. [20] These authors determined that, compared with patients with normoalbuminuria, those with an elevated UACR tended to be older, had higher rates of cardiovascular comorbidity and diabetes mellitus, and suffered from worse renal function. Even after adjustment for variables such as renal function and diabetes, an increased UACR was associated with a greater mortality risk.

In the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study, the incidence of myocardial infarction was higher in patients with microalbuminuria than in those with normal urinary albumin levels. [21] In a study by Rein et al, albuminuria was an important predictor of cardiovascular mortality even after adjusting for conventional risk factors. [22] Analysis of 1208 hypertensive, normoalbuminuric patients with type 2 diabetes from the BENEDICT trial also showed increased cardiovascular problems with any degree of measurable urinary albumin. [23]

Vascular calcification

Results from a study by Chiu et al of 225 proteinuric patients with type 2 diabetes mellitus indicated that vascular calcification, which can be particularly severe in nondialyzed patients with coexisting proteinuria and diabetes, is a prognostic indicator in early-stage type 2 diabetic nephropathy. [24]

In the study, 86% of patients were found to have coronary artery calcification, the degree of which was associated with older age, white ethnicity, and male sex. Fifty-four patients died during the follow-up period, which averaged 39 months.Univariate and multivariate analyses indicated that the degree of coronary artery calcification was, in relation to the calcification's severity, an independent predictor of all-cause mortality in the study's patients, with a 2.5-fold greater mortality risk found in subjects with a calcification score in the highest quartile.  [24]

Stroke risk

A study of 3939 subjects enrolled in the Chronic Renal Insufficiency Cohort (CRIC) study, a prospective observational cohort, found that proteinuria and albuminuria are better predictors of stroke risk in patients with chronic kidney disease than estimated glomerular filtration rate. In patients with albuminuria, treatment with renin-angiotensin blockers did not decrease stroke risk. [25]

COVID-19

Proteinuria is a common finding in patients with COVID-19. Of 646 COVID-19 infected patients in New York City, 42.1% were positive for proteinuria in dipstick results. [26] Cheng et al reported a prevalence of 43.9% in 701 patients upon hospital admission for COVID-19 infection. [27]

In a sample of 333 COVID-19 patients in Wuhan, China, proteinuria was identified in 65.8% (219 patients). When severity of illness was considered, proteinuria was present in only 43.8% of patients with moderate illness compared to 81.2% of severely ill patients and 85.7% of critically ill ones. Patients with acute kidney injury had the highest rate of proteinuria (88.6%). Although the majority of patients with proteinuria experienced remission (68.5%) within 3 weeks, proteinuria was associated with significantly increased mortality. [28]   

In a retrospective single-center study by Huart and colleagues of 153 patients hospitalized with COVID-19 and proteinuria upon admission, 14% of the patients had category 1 proteinuria (<  150 mg/g of urine creatinine), 42% had category 2 (between 150 and 500 mg/g) and 44% had category 3 (> 500 mg/g). Urine α1-microglobulin concentration was higher than 15 mg/g in 89% of patients. Total proteinura and urinary α1-microglobulin were associated with mortality, with the strongest association among a subgroup of patient with normal kidney function and without a urinary catheter. [26]  

Previous

Clinical Presentation

1. Glassock RJ, Fervenza FC, Hebert L, Cameron JS. Nephrotic syndrome redux. Nephrol Dial Transplant. 2015 Jan. 30 (1):12-7. [QxMD MEDLINE Link].

2. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015 Feb 24. 313 (8):837-46. [QxMD MEDLINE Link].

3. Springberg PD, Garrett LE Jr, Thompson AL Jr. Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med. 1982 Oct. 97(4):516-9. [QxMD MEDLINE Link].

4. Uehara K, Tominaga N, Shibagaki Y. Adult orthostatic proteinuria. Clin Kidney J. 2014 Jun. 7 (3):327-8. [QxMD MEDLINE Link]. [Full Text].

5. Naderi AS, Reilly RF. Primary care approach to proteinuria. J Am Board Fam Med. 2008 Nov-Dec. 21 (6):569-74. [QxMD MEDLINE Link].

6. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004 Jan. 65(1):30-9. [QxMD MEDLINE Link].

7. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol. 2007. 106(2):p32-7. [QxMD MEDLINE Link].

8. Schlöndorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol. 2009 Jun. 20(6):1179-87. [QxMD MEDLINE Link].

9. Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996 Jun. 27(6):765-75. [QxMD MEDLINE Link].

10. Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. 2009 Aug 6. [QxMD MEDLINE Link]. [Full Text].

11. Hebert LA, Birmingham DJ, Shidham G, et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-Hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract. 2009 Aug 12. 113(3):c177-c182. [QxMD MEDLINE Link]. [Full Text].

12. Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014 Mar. 9 (3):600-8. [QxMD MEDLINE Link]. [Full Text].

13. Zhang W, Feng LJ, Teng F, Li YH, Zhang X, Ran YG. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2020 Mar 5. 1-10. [QxMD MEDLINE Link].

14. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002 Mar. 39(3):445-59. [QxMD MEDLINE Link].

15. Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J Kidney Dis. 2006 Nov. 48(5):720-6. [QxMD MEDLINE Link].

16. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7. 298(17):2038-47. [QxMD MEDLINE Link].

17. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-Based Risk Assessment of APOL1 on Renal Disease. J Am Soc Nephrol. 2011 Nov. 22(11):2098-105. [QxMD MEDLINE Link].

18. Ruggenenti P, Perna A, Mosconi L. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl. 1997 Dec. 63:S54-7. [QxMD MEDLINE Link].

19. Hsu CY, Chinchilli VM, Coca S, Devarajan P, Ghahramani N, Go AS, et al. Post-Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. JAMA Intern Med. 2020 Jan 27. [QxMD MEDLINE Link].

20. Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009 Aug 15. 374(9689):543-50. [QxMD MEDLINE Link].

21. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study. Eur J Cardiovasc Prev Rehabil. 2004 Jun. 11(3):207-13. [QxMD MEDLINE Link].

22. Rein P, Saely CH, Zanolin D, Vonbank A, Drexel H. Albuminuria significantly predicts cardiovascular events in patients with type 2 diabetes independently from the baseline coronary artery state. European Heart Journal. Available at http://eurheartj.oxfordjournals.org/content/34/suppl_1/P5175. August 2013; Accessed: March 24, 2020.

23. Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol. 2012 Oct. 23(10):1717-24. [QxMD MEDLINE Link]. [Full Text].

24. Chiu YW, Adler SG, Budoff MJ, et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010 Mar 17. [QxMD MEDLINE Link].

25. Sandsmark DK, Messé SR, Zhang X, Roy J, Nessel L, Lee Hamm L, et al. Proteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort Study. Stroke. 2015 Aug. 46 (8):2075-80. [QxMD MEDLINE Link].

26. Huart J, Bouquegneau A, Lutteri L, Erpicum P, Grosch S, Résimont G, et al. Proteinuria in COVID-19: prevalence, characterization and prognostic role. J Nephrol. 2021 Apr. 34 (2):355-364. [QxMD MEDLINE Link]. [Full Text].

27. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020 May. 97 (5):829-838. [QxMD MEDLINE Link]. [Full Text].

28. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020 Jun. 31 (6):1157-1165. [QxMD MEDLINE Link]. [Full Text].

29. Ix JH, Wassel CL, Stevens LA, Beck GJ, Froissart M, Navis G, et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol. 2011 Jan. 6 (1):184-91. [QxMD MEDLINE Link].

30. Viswanathan G, Upadhyay A. Assessment of proteinuria. Adv Chronic Kidney Dis. 2011 Jul. 18 (4):243-8. [QxMD MEDLINE Link].

31. Methven S, Macgregor MS, Traynor JP, et al. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant. 2010 Mar 17. [QxMD MEDLINE Link].

32. Cirillo M. Evaluation of glomerular filtration rate and of albuminuria/proteinuria. J Nephrol. 2010 Mar-Apr. 23(2):125-32. [QxMD MEDLINE Link].

33. Avasare RS, Radhakrishnan J. Proteinuria as a surrogate marker for renal outcome: are we there yet?. Kidney Int. 2015 Dec. 88 (6):1228-1230. [QxMD MEDLINE Link]. [Full Text].

34. Kee YK, Yoon CY, Kim SJ, Moon SJ, Kim CH, Park JT, et al. Determination of the optimal target level of proteinuria in the management of patients with glomerular diseases by using different definitions of proteinuria. Medicine (Baltimore). 2017 Nov. 96 (44):e8154. [QxMD MEDLINE Link]. [Full Text].

35. Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019 May. 131 (4):251-260. [QxMD MEDLINE Link].

36. Feng C, Wu M, Chen Z, Yu X, Nie Z, Zhao Y, et al. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. 2019 Apr. 51 (4):655-669. [QxMD MEDLINE Link].

37. Krensky AM, Ingelfinger JR, Grupe WE. Peritonitis in childhood nephrotic syndrome: 1970-1980. Am J Dis Child. 1982 Aug. 136(8):732-6. [QxMD MEDLINE Link].

38. Chapman S, Taube D, Brown Z, Williams DG. Impaired lymphocyte transformation in minimal change nephropathy in remission. Clin Nephrol. 1982 Jul. 18(1):34-8. [QxMD MEDLINE Link].

39. Pneumococcal ACIP Vaccine Recommendations. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html. September 8, 2015; Accessed: April 28, 2018.

40. Roozbeh J, Banihashemi MA, Ghezlou M, et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail. 2010 Jan. 32(2):172-8. [QxMD MEDLINE Link].

41. Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail. 2010 Jan. 32(2):192-7. [QxMD MEDLINE Link].

42. Lewis EJ, Hunsicker LG, Bain RP. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published erratum appears in N Engl J Med 1993 Jan 13;330(2):152]. N Engl J Med. 1993 Nov 11. 329(20):1456-62. [QxMD MEDLINE Link].

43. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. ALYSIS. 1997 Sep 1. 127(5):337-45. [QxMD MEDLINE Link].

44. Bakris GL, et al; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1. 314 (9):884-94. [QxMD MEDLINE Link].

45. Pozzi C. Treatment of IgA nephropathy. J Nephrol. 2016 Feb. 29 (1):21-5. [QxMD MEDLINE Link].

46. [Guideline] Kidney Disease: Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. KDIGO. Available at http://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. January 2013; Accessed: March 24, 2020.

47. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol. 1989 Jun. 256 (6 Pt 2):F1015-20. [QxMD MEDLINE Link].

48. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep. 54 (3):889-96. [QxMD MEDLINE Link].

49. Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol. 2013 Oct. 76 (4):573-9. [QxMD MEDLINE Link].

50. Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009 Mar. 20 (3):655-64. [QxMD MEDLINE Link].

51. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010 Nov 6. 376(9752):1543-51. [QxMD MEDLINE Link].

52. de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol. 2013 Nov. 24(11):1863-71. [QxMD MEDLINE Link]. [Full Text].

53. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2009 Aug 7. [QxMD MEDLINE Link].

54. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003 Mar. 41(3):565-70. [QxMD MEDLINE Link].

55. Vegter S, Perna A, Postma MJ, et al. Sodium Intake, ACE Inhibition, and Progression to ESRD. J Am Soc Nephrol. 2012 Jan. 23(1):165-73. [QxMD MEDLINE Link].

56. Klahr S, Levey AS, Beck GJ. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31. 330(13):877-84. [QxMD MEDLINE Link].

57. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev. 2007 Oct 17. CD002181. [QxMD MEDLINE Link].

58. Waller KV, Ward KM, Mahan JD, Wismatt DK. Current concepts in proteinuria. Clin Chem. 1989 May. 35 (5):755-65. [QxMD MEDLINE Link].

59. Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996 Jun. 27(6):765-75. [QxMD MEDLINE Link].

60. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011 Nov. 22(11):2098-105. [QxMD MEDLINE Link]. [Full Text].

61. Gorriz JL, Martinez-Castelao A. Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando). 2012 Jan. 26 (1):3-13. [QxMD MEDLINE Link].

62. Shamseddin MK, Knoll GA. Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol. 2011 Jul. 6 (7):1786-93. [QxMD MEDLINE Link].

63. Miner JH. Glomerular basement membrane composition and the filtration barrier. Pediatr Nephrol. 2011 Sep. 26 (9):1413-7. [QxMD MEDLINE Link].

64. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol. 2008 Dec. 295 (6):F1589-600. [QxMD MEDLINE Link].

65. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May. 63 (5):713-35. [QxMD MEDLINE Link].

66. Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. Am Fam Physician. 2016 Mar 15. 93 (6):479-85. [QxMD MEDLINE Link].

67. Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, et al. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opin Investig Drugs. 2010 Sep. 19 (9):1027-37. [QxMD MEDLINE Link].

68. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 Jul. 98 (1):209-218. [QxMD MEDLINE Link]. [Full Text].

Media Gallery

of 0

Tables

Back to List

Author

Beje Thomas, MD Assistant Professor, Department of Medicine (Nephrology), Georgetown University School of Medicine; Physician in Transplant Nephrology, Medstar Transplant Institute

Beje Thomas, MD is a member of the following medical societies: American Society of Nephrology, American Society of Transplantation, National Kidney Foundation

Disclosure: Nothing to disclose.

Coauthor(s)

Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF Clinical Professor of Medicine, Section of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine; Research Director, Internal Medicine Training Program, Advocate Christ Medical Center; Consulting Staff, Associates in Nephrology, SC

Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF is a member of the following medical societies: American Heart Association, American Medical Association, American Society of Hypertension, American Society of Nephrology, Chicago Medical Society, Illinois State Medical Society, National Kidney Foundation, Society of General Internal Medicine

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Astra Zeneca<br/>Author for: UpToDate, ACP Smart Medicine, Elsevier, McGraw-Hill, Wolters Kluwer.

Chief Editor

Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Interim Chair, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Tejas Desai, MD Staff Nephrologist, WG (Bill) Hefner VA Medical Center

Tejas Desai, MD is a member of the following medical societies: American College of Physicians, American Society of Nephrology

Disclosure: Nothing to disclose.

Pankaj Jawa, MD Assistant Professor of Medicine, Division of Nephrology and Hypertension, The Brody School of Medicine at East Carolina University

Pankaj Jawa, MD is a member of the following medical societies: American Society of Hypertension, American Society of Nephrology, American Society of Transplantation, National Kidney Foundation

Disclosure: Nothing to disclose.

Acknowledgements

George R Aronoff, MD Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Kevin McLaughlin, MBChB, PhD, MSc Associate Professor, Assistant Dean, Department of Medicine, University of Calgary Faculty of Medicine, Calgary Health Region

Kevin McLaughlin, MBChB, PhD, MSc is a member of the following medical societies: American Society of Nephrology, American Society of Transplantation, and College of Physicians and Surgeons of Alberta

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

What is a glomerular disease characterized by a marked loss of protein in the urine?

What is glomerular kidney disease?

What causes glomerular proteinuria?

What is the name of the condition when proteins are detected from the urine quizlet?